{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:59:03Z","timestamp":1773435543273,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Bayer Yakuhin, Ltd."},{"DOI":"10.13039\/100015377","name":"Nihon Medi-Physics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015377","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medtronic Japan"},{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Takeda Pharma"},{"name":"CSL Behring"},{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Otsuka Pharma"},{"DOI":"10.13039\/501100002806","name":"Carl Zeiss Meditec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002806","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Philips Electronics Japan"},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Siemens Healthcare"},{"DOI":"10.13039\/501100012351","name":"Mitsubishi-Tanabe Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jjcc.2019.06.003","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T07:53:05Z","timestamp":1564386785000},"page":"501-506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world outcomes of rivaroxaban treatment in patients with nonvalvular atrial fibrillation and worsening renal function"],"prefix":"10.1016","volume":"74","author":[{"given":"Jyoji","family":"Nakagawara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanari","family":"Kitazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Minematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Murakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Takeichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Kidani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Sunaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2019.06.003_bib0100","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0105","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijcard.2008.06.029","article-title":"Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination","volume":"137","author":"Inoue","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0110","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1253\/circj.CJ-66-0092","article-title":"Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013)","volume":"78","author":"JCS Joint Working Group","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0115","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"Kirchhof","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0120","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0125","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0130","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0135","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation \u2013 the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0140","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0145","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/CIRCULATIONAHA.108.816082","article-title":"Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"119","author":"Go","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0150","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0155","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/ehjqcco\/qcx032","article-title":"Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry","volume":"4","author":"Kodani","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.116.021890","article-title":"On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF","volume":"134","author":"Fordyce","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0165","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/joa3.12034","article-title":"Design and baseline characteristics of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS)","volume":"34","author":"Ogawa","year":"2018","journal-title":"J Arrhythm"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0170","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jjcc.2019.01.001","article-title":"Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS)","volume":"74","author":"Ikeda","year":"2019","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0175","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0180","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0185","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2019.06.003_bib0190","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jamacardio.2016.1170","article-title":"Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial","volume":"1","author":"Hijazi","year":"2016","journal-title":"JAMA Cardiol"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S091450871930173X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S091450871930173X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:01:02Z","timestamp":1760274062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S091450871930173X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S091450871930173X"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2019.06.003","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes of rivaroxaban treatment in patients with nonvalvular atrial fibrillation and worsening renal function","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2019.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.","name":"copyright","label":"Copyright"}]}}